Anticancer research · 2004
Biochemical analysis and subcellular distribution of E-cadherin-catenin in adenocarcinomas of the gastro-oesophageal junction.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wijnhoven B P L, Tucker E T, Dinjens W N M, Tilanus H W, Pignatelli M
Аннотация
BACKGROUND: Disturbances in the expression or structure of E-cadherin-catenin, a cell-cell adhesion complex, perturb its cell adhesive function.
MATERIALS AND METHODS: We studied the expression and distribution of the E-cadherin-catenin complex in 24 adenocarcinomas of the gastro-oesophageal junction (GOJ) by immunohistochemistry and Western blotting of the Triton X-100-soluble (membrane bound) and insoluble fractions (cytoskeleton bound).
RESULTS: Immunohistochemistry demonstrated redistribution of E-cadherin, alpha-, beta- and gamma-catenin from the membrane to the cytoplasm in 13/24 (54%), 18/24 (75%), 16/24 (67%) and 15/24 (63%) tumours, respectively. Five tumours showed nuclear localisation of beta-catenin. Western blotting showed redistribution between the TX-100 soluble and insoluble fraction of E-cadherin and the catenins in 5/11 (45%), 4/10 (40%), 5/11 (45%) and 5/11 (45%) tumours, respectively.
CONCLUSION: Loss of membrane bound E-cadherin-catenin is frequently observed in adenocarcinomas of the GOJ and this may reflect loss of function of the E-cadherin-catenin complex in these cancers.
MATERIALS AND METHODS: We studied the expression and distribution of the E-cadherin-catenin complex in 24 adenocarcinomas of the gastro-oesophageal junction (GOJ) by immunohistochemistry and Western blotting of the Triton X-100-soluble (membrane bound) and insoluble fractions (cytoskeleton bound).
RESULTS: Immunohistochemistry demonstrated redistribution of E-cadherin, alpha-, beta- and gamma-catenin from the membrane to the cytoplasm in 13/24 (54%), 18/24 (75%), 16/24 (67%) and 15/24 (63%) tumours, respectively. Five tumours showed nuclear localisation of beta-catenin. Western blotting showed redistribution between the TX-100 soluble and insoluble fraction of E-cadherin and the catenins in 5/11 (45%), 4/10 (40%), 5/11 (45%) and 5/11 (45%) tumours, respectively.
CONCLUSION: Loss of membrane bound E-cadherin-catenin is frequently observed in adenocarcinomas of the GOJ and this may reflect loss of function of the E-cadherin-catenin complex in these cancers.